Shares of NxStage Medical, Inc. (NASDAQ:NXTM) saw an uptick in trading volume on Tuesday . 3,848,322 shares traded hands during mid-day trading, an increase of 409% from the previous session’s volume of 756,498 shares.The stock last traded at $29.65 and had previously closed at $29.30.

Several brokerages have issued reports on NXTM. Zacks Investment Research raised shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Tuesday, February 5th. BidaskClub downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, November 28th.

The company has a market capitalization of $1.98 billion, a PE ratio of -136.36 and a beta of 0.25.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc lifted its stake in NxStage Medical by 1.7% in the third quarter. Vanguard Group Inc now owns 5,970,746 shares of the medical device company’s stock worth $166,523,000 after purchasing an additional 101,806 shares during the last quarter. Vanguard Group Inc. lifted its stake in NxStage Medical by 1.7% in the third quarter. Vanguard Group Inc. now owns 5,970,746 shares of the medical device company’s stock worth $166,523,000 after purchasing an additional 101,806 shares during the last quarter. BlackRock Inc. lifted its stake in NxStage Medical by 1.6% in the fourth quarter. BlackRock Inc. now owns 5,424,200 shares of the medical device company’s stock worth $155,241,000 after purchasing an additional 85,905 shares during the last quarter. Millennium Management LLC lifted its stake in NxStage Medical by 45.9% in the fourth quarter. Millennium Management LLC now owns 1,792,232 shares of the medical device company’s stock worth $51,294,000 after purchasing an additional 563,730 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in NxStage Medical by 56.3% in the third quarter. JPMorgan Chase & Co. now owns 1,187,250 shares of the medical device company’s stock worth $33,113,000 after purchasing an additional 427,745 shares during the last quarter. 80.34% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2019/02/21/nxstage-medical-nxtm-sees-large-volume-increase.html.

About NxStage Medical (NASDAQ:NXTM)

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Featured Story: Channel Trading

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.